Descubre lo que realmente dicen los números — antes que el mercado
Analizar ahora
Sentimiento de noticias
¿Las noticias de hoy son una señal de compra o una alerta?
Analizar ahora
Comprar / Mantener / Vender
¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.
Analizar ahora
Evaluación de riesgos
Descubre riesgos ocultos antes de que afecten a tu cartera.
Analizar ahora
Valor justo
¿Esta acción está barata, correctamente valorada o sobrevalorada?
Analizar ahora
Últimos análisis de IA sobre APTOSE BIOSCI.JAN 2025
Resumen de la Calificación de Analistas
Comprar
Compra Fuerte
Comprar
Mantener
Vender
Venta Fuerte
0
10
1
0
0
Sin cotización
28.04.2026 15:33
Cotizaciones actuales de APTOSE BIOSCI.JAN 2025
Bolsa
Ticker
Moneda
Última operación
Precio
Variación diaria
TSX
APS.TO
CAD
28.04.2026 15:33
2,37 CAD
0,02 CAD
+0,85 %
Flotación y Liquidez de las Acciones
Flotación Libre72,70 %
Acciones en Flotación1,86 M
Acciones en Circulación2,55 M
Perfil de la empresa para APTOSE BIOSCI.JAN 2025 Acción
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
